Combination therapy improves survival outcomes for patients with acute myeloid leukemia

(University of Texas M. D. Anderson Cancer Center) A combination regimen of venetoclax and azacitidine was safe and improved overall survival (OS) over azacitidine alone in certain patients with acute myeloid leukemia (AML), according to the Phase III VIALE-A trial led by The University of Texas MD Anderson Cancer Center.